FDA Approves AstraZeneca Drug With New Approach to Lowering High Blood Pressure
Frank Vinluan / medcitynews - AstraZeneca’s Baxfendy is the first FDA-approved drug in a new class of medicines called aldosterone synthase inhibitors. The new mechanism of action is important for patients and for AstraZeneca, which has been looking for new drugs with blockbuster pote…
AI Summary: The FDA has approved a first-in-class oral agent that uses a novel mechanism to lower resistant hypertension, offering an alternative for patients who haven’t responded to standard therapies. The move expands treatment options and signals renewed industry focus on innovative vascular targets — finally something for stubborn blood pressure to complain about.
CMS finalizes major changes to ACA exchanges, including greater access to catastrophic plans
Rebecca Pifer Parduhn / healthcaredive - The Trump administration continues to open the doors to the cheap, high-deductible coverage, to the worry of insurance experts and stakeholders in the healthcare industry.
AI Summary: In a sweeping final rule, CMS loosened constraints on ACA marketplace offerings to broaden consumer choice — including expanded access to catastrophic plans and relaxed limits on non-standard plan designs. The changes aim to reshape the 2027 exchanges, boost affordability and enrollment flexibility, and hand insurers new product wiggle room while regulators expect close scrutiny.
- CMS final rule loosens plan design, expands catastrophic access (4)
- Insurers exit and consumers pivot to cheaper alternatives (3)
- Rising costs and shrinking ACA enrollment threaten markets (4)
CMS final rule loosens plan design, expands catastrophic access
Insurers exit and consumers pivot to cheaper alternatives
Rising costs and shrinking ACA enrollment threaten markets
Kicking Off the Cancer Planners Forum in Geneva – UICC
oncodaily - Union for International Cancer Control (UICC) shared a post on LinkedIn: “We’re excited to kick off the Cancer Planners Forum in Geneva today! Convening national leaders responsible for cancer control planning, […]
AI Summary: The UICC Cancer Planners Forum in Geneva brought policymakers, clinicians, and public‑health leaders together to map national cancer control strategies, prioritize cervical cancer elimination, and foster implementation partnerships. The forum emphasized practical planning, stakeholder engagement, and resource‑sensitive solutions to turn plans into measurable improvements in prevention, screening, and care delivery.
- Cervical cancer elimination and clinical partnerships (3)
- Forum launch and wrap-up in Geneva (3)
- National cancer planning and policy priorities (3)
- All Other Stories